Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of “Hold” by Brokerages

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been assigned an average recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $58.00.

A number of research analysts have issued reports on PSTV shares. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a research note on Saturday, April 4th. HC Wainwright restated a “buy” rating and set a $25.00 price target (down from $50.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. D. Boral Capital restated a “hold” rating on shares of Plus Therapeutics in a research note on Tuesday, March 31st. Finally, Ascendiant Capital Markets cut their price target on shares of Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PSTV. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics during the second quarter worth $41,000. Susquehanna International Group LLP purchased a new position in shares of Plus Therapeutics during the third quarter worth $46,000. Scientech Research LLC purchased a new position in shares of Plus Therapeutics during the third quarter worth $100,000. XTX Topco Ltd purchased a new position in shares of Plus Therapeutics during the fourth quarter worth $127,000. Finally, State Street Corp raised its holdings in shares of Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares during the last quarter. Hedge funds and other institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Trading Down 0.2%

Shares of Plus Therapeutics stock opened at $5.83 on Wednesday. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $23.42. The firm has a market capitalization of $40.11 million, a price-to-earnings ratio of -2.53 and a beta of 1.40. The firm’s 50 day simple moving average is $5.78 and its two-hundred day simple moving average is $9.26.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.97 million. On average, sell-side analysts predict that Plus Therapeutics will post -3.66 EPS for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.